Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Ingrid Wertz - Principal Scientist, Discovery Oncology & Early Discovery Biochemistry

Ingrid Wertz

Principal Scientist, Discovery Oncology & Early Discovery Biochemistry

Postdoc Mentor
"Identifying subtle variations that promote significant biological consequences has always fascinated me. The key is to distinguish which small changes matter and which ones don't; this knowledge can then facilitate the development of therapeutics."
Years at Genentech
Awards & Honors

I began my career at Genentech as an NIH Biotechnology Training grant intern and had the opportunity to complete my graduate studies at Genentech.  Here I witnessed the transformation of scientific discoveries into therapeutic agents.  In this way I learned that rigorous scientific experimentation is the foundation for rational drug design.

During my medical training I experienced how illness can transform the lives of patients and saw first hand the impact that effective medicines can have. After completing my graduate and medical studies I chose to return to Genentech as a scientist in order to help patients through scientific discoveries. My aims are to understand the molecular basis of normal physiology and of disease and to translate those findings into novel therapeutics.

Postdoctoral Mentor

Postdoctoral projects in our lab are focused on characterizing protein alterations that promote human disease. These pathogenic changes may include aberrant enzymatic activity, altered protein expression levels, or post-translational modifications such as phosphorylation or ubiquitination. Oncoproteins, tumor suppressors, and components of homeostatic signaling cascades are often modified by such mechanisms. Thus improper regulation of proteins can promote inflammatory disorders, cancer, and other disease states.

Our laboratory uses and develops a variety of molecular, cellular, genetic, biophysical, proteomic, and in vivo systems to achieve our research goals. As such we have active collaborations with external groups and within Genentech including Protein Chemistry and Proteomics, Medicinal Chemistry, Research Oncology, Structural Biology, Antibody Engineering, Molecular Biology, and Pathology. In this way, we aim to elucidate the molecular mechanisms by which aberrant protein modifications contribute to disease.

Featured Publication

USP7 small-molecule inhibitors interfere with ubiquitin binding.

Nature. 2017 Oct 26;550(7677):534-538.

Kategaya L, Di Lello P, Rougé L, Pastor R, Clark KR, Drummond J, Kleinheinz T, Lin E, Upton JP, Prakash S, Heideker J, McCleland M, Ritorto MS, Alessi DR, Trost M, Bainbridge TW, Kwok MCM, Ma TP, Stiffler Z, Brasher B, Tang Y, Jaishankar P, Hearn BR, Renslo AR, Arkin MR, Cohen F, Yu K, Peale F, Gnad F, Chang MT, Klijn C, Blackwood E, Martin SE, Forrest WF, Ernst JA, Ndubaku C, Wang X, Beresini MH, Tsui V, Schwerdtfeger C, Blake RA, Murray J, Maurer T, Wertz IE.